TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sagimet Biosciences, Inc. Class A ( (SGMT) ) just unveiled an announcement.
On November 13, 2025, Sagimet Biosciences reported its third-quarter financial results and provided corporate updates, including ongoing clinical trials. The company is conducting a Phase 1 trial to assess the pharmacokinetics of a combination of denifanstat and resmetirom, with results expected in the first half of 2026. Additionally, Sagimet’s partner, Ascletis, plans to submit a New Drug Application in China for denifanstat to treat acne. The company also announced leadership promotions and highlighted recent presentations at medical conferences, showcasing positive outcomes in clinical trials for both MASH and acne.
The most recent analyst rating on (SGMT) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.
Spark’s Take on SGMT Stock
According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral.
Sagimet Biosciences’ overall score reflects substantial financial difficulties marked by persistent losses and reliance on external funding. While technical indicators show short-term bullish momentum, the lack of profitability and negative equity pose significant long-term risks. Valuation metrics further highlight the challenges in viewing this stock as an attractive investment.
To see Spark’s full report on SGMT stock, click here.
More about Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways. The company is working on FASN inhibitors, such as denifanstat and TVB-3567, to treat conditions like metabolic dysfunction associated steatohepatitis (MASH) and acne.
Average Trading Volume: 566,431
Technical Sentiment Signal: Buy
Current Market Cap: $273.4M
For an in-depth examination of SGMT stock, go to TipRanks’ Overview page.